Evidence map›Paper›PMID 27707930›Full record

ArticleJournal of virology2016

Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.

Meihui Xu, Roland Züst, Ying Xiu Toh, Jennifer M Pfaff, Kristen M Kahle, Edgar Davidson, Benjamin J Doranz, Sumathy Velumani, Farhana Tukijan, Cheng-I Wang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Neurological Manifestations of Perinatal Dengue.Newborn (Clarksville, Md.) · 2023
    Article
  6. Article
  7. Review
  8. CD27iScience · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Meihui XuSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Roland ZüstSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Ying Xiu TohSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Jennifer M PfaffIntegral Molecular, Philadelphia, Pennsylvania, USA.
Kristen M KahleIntegral Molecular, Philadelphia, Pennsylvania, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, Pennsylvania, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, Pennsylvania, USA.
Sumathy VelumaniSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Farhana TukijanSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Cheng-I WangSingapore Immunology Network, Agency for Science Technology and Research, Singapore.
Katja FinkSingapore Immunology Network, Agency for Science Technology and Research, Singapore Katja_fink@immunol.a-star.edu.sg.ORCID http://orcid.org/0000-0002-3571-0390
Agency for Science, Technology and Research · SGIntegral Molecular (United States) · US

Funding

NIAID NIH HHS HHSN272200900055C
6 · The paper itself

Abstract

Half of the world's population is exposed to the risk of dengue virus infection. Although a vaccine for dengue virus is now available in a few countries, its reported overall efficacy of about 60% is not ideal. Protective immune correlates following natural dengue virus infection remain undefined, which makes it difficult to predict the efficacy of new vaccines. In this study, we address the protective capacity of dengue virus-specific antibodies that are produced by plasmablasts a few days after natural secondary infection. Among a panel of 18 dengue virus-reactive human monoclonal antibodies, four groups of antibodies were identified based on their binding properties. While antibodies targeting the fusion loop of the glycoprotein of dengue virus dominated the antibody response, two smaller groups of antibodies bound to previously undescribed epitopes in domain II of the E protein. The latter, largely serotype-cross-reactive antibodies, demonstrated increased stability of binding at pH 5. These antibodies possessed weak to moderate neutralization capacity in vitro but were the most efficacious in promoting the survival of infected mice. Our data suggest that the cross-reactive anamnestic antibody response has a protective capacity despite moderate neutralization in vitro and a moderate decrease of viremia in vivo IMPORTANCE: Antibodies can protect from symptomatic dengue virus infection. However, it is not easy to assess which classes of antibodies provide protection because in vitro assays are not always predictive of in vivo protection. During a repeat infection, dengue virus-specific immune memory cells are reactivated and large amounts of antibodies are produced. By studying antibodies cloned from patients with heterologous secondary infection, we tested the protective value of the serotype-cross-reactive "recall" or "anamnestic" response. We found that results from in vitro neutralization assays did not always correlate with the ability of the antibodies to reduce viremia in a mouse model. In addition, a decrease of viremia in mice did not necessarily improve survival. The most protective antibodies were stable at pH 5, suggesting that antibody binding in the endosomes, after the antibody-virus complex is internalized, might be important to block virus spread in the organism.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCross ReactionsDengueDengue VirusDisease Models, AnimalEpitope MappingEpitopesGene ExpressionHumansHydrogen-Ion ConcentrationImmunity, HumoralImmunologic MemoryMiceAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesE protein TH Sman, Dengue virusViral Envelope Proteins

Identifiers

PMID27707930
PMCPMC5126370
OpenAlexW2528731370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.